Enanta Pharmaceuticals, Inc.

NasdaqGS:ENTA Rapporto sulle azioni

Cap. di mercato: US$197.9m

Enanta Pharmaceuticals Crescita futura

Future criteri di controllo 1/6

Si prevede che gli utili di Enanta Pharmaceuticals diminuiranno a 2.7% all'anno, mentre si prevede che i suoi ricavi annuali cresceranno a 12.8% all'anno. Si prevede che l'EPS crescerà di 2.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà -64.2% in 3 anni.

Informazioni chiave

-2.7%

Tasso di crescita degli utili

2.5%

Tasso di crescita dell'EPS

Biotechs crescita degli utili28.3%
Tasso di crescita dei ricavi12.8%
Rendimento futuro del capitale proprio-64.2%
Copertura analitica

Good

Ultimo aggiornamento09 Oct 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

Oct 05
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

Aug 08
Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%

Jul 24
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Jun 19
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

May 09
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Mar 05
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 12
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Aug 13
Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Feb 24
We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Feb 08
Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Nov 25
Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Oct 25
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Enanta starts mid-stage trial of EDP-938 for RSV infection

Oct 03

Enanta Pharma FQ3 2022 Earnings Preview

Aug 07

Enanta potential COVID drug shows safety in healthy people in early-stage trial

Jul 29

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Jul 04
Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Enanta: Slow Drip

May 17

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Feb 04
Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Nov 25
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:ENTA - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
9/30/2027116-112-276N/A4
9/30/202681-154-230N/A4
9/30/202574-120-142-1008
9/30/202471-112-121-848
6/30/202472-115-100-90N/A
3/31/202473-132-113-107N/A
12/31/202374-138-99-93N/A
9/30/202379-134-112-103N/A
6/30/202381-132-106-97N/A
3/31/202381-125-102-95N/A
12/31/202282-121-112-107N/A
9/30/202286-122-87-85N/A
6/30/202289-120-91-90N/A
3/31/202292-112-91-90N/A
12/31/202193-101-69-68N/A
9/30/202197-79-71-70N/A
6/30/202197-84-65-64N/A
3/31/202194-74-40-39N/A
12/31/2020102-58-21-20N/A
9/30/2020122-3667N/A
6/30/202015023031N/A
3/31/2020176243538N/A
12/31/2019188344854N/A
9/30/2019205466671N/A
6/30/2019221658591N/A
3/31/2019234788893N/A
12/31/2018238865255N/A
9/30/2018207722629N/A
6/30/2018215815658N/A
3/31/201816652N/A49N/A
12/31/201713134N/A54N/A
9/30/201710318N/A53N/A
6/30/201740-21N/A-7N/A
3/31/201746-13N/A-4N/A
12/31/201650-10N/A9N/A
9/30/20168822N/A36N/A
6/30/20169029N/A36N/A
3/31/20168733N/A23N/A
12/31/201513263N/A112N/A
9/30/201516179N/A77N/A
6/30/201514968N/A74N/A
3/31/2015180116N/A123N/A
12/31/201412482N/A20N/A
9/30/20144834N/A20N/A
6/30/20144635N/A23N/A
3/31/20146-19N/A-18N/A
12/31/20135-19N/A-4N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ENTA rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che ENTA rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che ENTA rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ENTA ( 12.8% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ENTA ( 12.8% all'anno) crescerà più lentamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Si prevede che ENTA non sarà più redditizia tra 3 anni.


Scoprire le aziende in crescita